This product page is intended for qualified business, laboratory, or research-related inquiry. Availability and permitted use depend on destination country and local regulations.
Confirm product name, preferred specification, quantity, and packaging requirement before quotation.
Ask for available specification sheet, packaging details, or product-related quality documentation.
Use Inquiry Cart or the quote form so our team can reply with availability, lead time, and shipping communication.
Mazdutide is a dual agonist of the GLP-1receptor and glucagon receptor. It is an analog of oxyntomodulin (OXM).
The drug is developed by Eli Lilly and is currently in multiple Phase III studies.
In May 2025, a result of Phase III study has shown that once-weekly mazdutide led to clinically relevant reductions in body weight in Chinese adults with overweight or obesity.
Request a Quote
Send your quantity, destination country, and preferred contact method. Our team will reply with availability and quotation details.